NCT06253585

Precision Resuscitation With Crystalloids in Sepsis

Precision Resuscitation With Crystalloids in Sepsis (PRECISE)
Emory University·ClinicalTrials.gov·otherNot yet recruiting
View on ClinicalTrials.gov
Study focus
Disease/Condition
Sepsis
Drug/Device/Intervention
Algorithm Alarm- Crystalloids
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
Emory University
Location
Atlanta,Atlanta,Atlanta,Atlanta,Decatur,Johns Creek,Lithonia, United States of America
Timeline & enrollment
Phase
N/A
Start date
May 01, 2024
End date
Apr 30, 2025
Enrollment
1115 participants
Primary outcome

Thirty-day mortality

Summary

Fluids are one of the most common treatments given to patients in the hospital. Fluids are
 especially important in treating patients with sepsis. Multiple clinical studies have
 compared the two main types of fluids used in sepsis (normal saline and balanced
 crystalloids). However, these studies have not found a clear benefit of one type of fluid
 versus the other. Which fluid should be given to which patient is an essential question
 because of the ubiquity of this intervention. Even a small difference in mortality could
 drastically change the standards of care given the national (and worldwide) scale of this
 intervention. The investigators have developed an algorithm that uses bedside vital signs
 (temperature, heart rate, respiratory rate, and blood pressure) to identify a group of
 patients (Group D) who have a significant mortality benefit from balanced crystalloids. The
 study randomizes adult patients in emergency departments across 6 Emory hospitals belonging
 to Group D to intervention versus usual care. The intervention arm involves a prompt to
 clinicians to use balanced crystalloids rather than normal saline.

ICD-10 classifications
Other sepsisSepsis, unspecifiedOther specified sepsisCandidal sepsisPuerperal sepsis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06253585
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06253585 through Pure Global AI's free database. This phase not specified trial is sponsored by Emory University and is currently Not yet recruiting. The study focuses on Sepsis. Target enrollment is 1115 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.